**[167] CUREWIZE - COMMERCIALIZING MIRNA LAB TESTS FOR PERSONALIZED TREATMENT OF CANCERS**

**Jennifer Yarden1, Nir Dotan2, Keren Shichrur2, Smadar Avigad3, 1 Bioshai, 2 Curewize, 3 Schneider Children's Medical Center of Israel**

* **Investment Rational** Curewize is commercializing ProALLTM, a groundbreaking lab test for aiding in treatment decisions and monitoring of acute lymphoblastic leukemia (ALL). Curewize gains value from management experienced in successfully taking a lab test from concept to sales and a large biomarker pipeline for several cancers. Curewize is collaborating with an oncology group for the validation of ProALL on additional ALL patients.
* **Business Strategy** ProALL will be marketed to centralized oncology groups for identifying ALL patients who need intense treatment. In 2018, ProALL is planned to be available from laboratories in USA and Europe. By 2020, Curewize aims to launch ProALL’s monitoring assay. Curewize R&D team are developing additional tests for aiding in the personalized treatment of other cancer patients, increasing long term revenues.
* **Core Technology** ALL treatment intensity varies by patient’s risk to relapse and determined by quantifying residual leukemia cells, 1-3 months after starting treatment. ProALL determines patient’s risk to relapse 1-3 days from diagnosis. ProALL answers need for a rapid, straightforward and less expensive test. ProALL measures microRNA that controls genes involved in cancer by using standard technology called Quantitative Reverse Transcription PCR.
* **Product Profile/Pipeline** Curewize product pipeline includes a test for long-term monitoring of ALL patients for molecular relapse during and after treatment. A clinical trial using stored specimens is being pursued and a prospective clinical trial is at initial stages. Curewize is pursuing the very large potential of our R&D findings on microRNA biomarkers for the personalized treatment of other cancers.
* **What's Next?** Curewize is nearing the commercialization of ProALL and intends to receive CE during 2017. Additional funding of ~2.0 million dollars is required for preparing reimbursement strategy, marketing activities, transfer and qualification of ProALL in USA labs and the clinical development of pipeline products for additional cancers. Large oncology groups will be approached for incorporating ProALL in their treatment protocol.